Your browser doesn't support javascript.
loading
To Maintain Formulation Composition Similarity of Coated Tablets of Different Strengths: Should Coating be Based on Core Tablet Weight or Surface Area?
Reddy, Jay Poorna; Vyas, Gunjan; Patel, Rakshit; Rana, Sandeep; Mansuri, Niyaz; Dimuthu, Jayawickrama; Shah, Tejas; Desai, Divyakant.
Afiliação
  • Reddy JP; Bristol-Myers Squibb Co., New Brunswick, New Jersy, 08903-0191, USA.
  • Vyas G; Gilead Sciences Inc., Foster City, California, 94404, USA.
  • Patel R; Piramal Pharma Solutions, Ahmedabad, Gujarat, India.
  • Rana S; Novartis, Hyderabad, India.
  • Mansuri N; Piramal Pharma Solutions, Ahmedabad, Gujarat, India.
  • Dimuthu J; Piramal Pharma Solutions, Ahmedabad, Gujarat, India.
  • Shah T; Piramal Pharma Solutions, Ahmedabad, Gujarat, India.
  • Desai D; Bristol-Myers Squibb Co., New Brunswick, New Jersy, 08903-0191, USA.
Pharm Res ; 37(10): 201, 2020 Sep 24.
Article em En | MEDLINE | ID: mdl-32968862
ABSTRACT

PURPOSE:

As per the Japanese or SUPAC guidance to maintain formulation composition similarity across tablet strengths, the coating should be applied based on the core tablet surface area or weight, respectively. These two coating approaches were compared by evaluating protective effects of coating on the light stability of three model compounds.

METHODS:

Core tablets of three light sensitive drugs, nifedipine, rosuvastatin calcium, and montelukast sodium were coated either with PVA-based Opadry® II white or Opadry® II beige. The coated tablets were exposed to light up to three ICH cycles.

RESULTS:

For Opadry® II white, the surface area based coating provided consistent light protection across tablet strengths when the coating amount was more than 0.1 mg/mm2 compared to that based on core tablet weights. For Opadry® II beige, both approaches gave comparable and better light protection due to presence of iron oxides. The light protection by Opadry® II white could be because of physical barrier of coating, which was uniform across the strengths when it was based on core tablet surface area.

CONCLUSION:

For a routine tablet formulation development with Opadry color coating, it does not matter whether the coating is applied based on the core tablet surface area or weight.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comprimidos / Composição de Medicamentos Limite: Humans Idioma: En Revista: Pharm Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comprimidos / Composição de Medicamentos Limite: Humans Idioma: En Revista: Pharm Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos